

Östersund

ÖFK sponsors is a step closer to a factory in Östersund.

15 december 2023 05:00

There is no production yet but shares worth several million kroner can save ÖFK's elite license. -Well, we have contributed to taking a step closer to a factory in Östersund with a patent for a version of pain-relieving aspirin. The first product will be a wet wipe, says Roar Adelsten, CEO of Auxesis Pharma Holding AB (publ).



Maria LindholmText



Roar Adelsten, CEO of newly started Auxesis Pharma. Photo: Therése Särnbäck

Roar Adelsten, CEO of newly started Auxesis Pharma, plans to produce pain-relieving wet wipes in Östersund.

He and his partners were in Östersund in connection with the last home match in the super league. They didn't get to see a match, but they were presented to the audience before kick-off as financial saving angels. In August, ÖFK presented the news that the club had received a donation in the form of 110,000 shares in the company Auxesis Pharma. The shares were estimated at a value of SEK 6 million. The club sold most of the shares and was thus able to increase the pot required to save the economy, reportedly by SEK 4.3 million.

Since then, the company has had regular contact with the municipality. The plans are to establish production in Östersund. However, to start manufacturing medicines, both a patent and approval from the Swedish Medicines Agency are required. And now Auxesis has registered the former.

- We have registered the active parts, says Roar Adelsten, CEO of the newly started company.

The idea is to stabilize the painkiller aspirin, which is normally dissolved in the form of an effervescent tablet. Instead, Auxesis wants to develop a way to manufacture the pain-relieving medicine in products that are applied directly to the skin. Ointment has been mentioned before, but a wet wipe will be manufactured first, according to Roar Adelsten.

- You can imagine that you burn yourself on nettles or now regarding this Christmas season, when you take dishes out of the oven and burn yourself. We also consider lighter burns such as sun damage, he says.

With the patent registration, the company is now looking for a sub-contractor that can produce the wet wipes on a small scale, alternatively they can be produced in the laboratory facilities that the company has access to at the Karolinska Institute, according to Roar Adelsten.

The next step is to test them on humans and apply for market approval from the Swedish Medicines Agency.

- At New Year's we will make a decision whether we will rent an existing premises in Östersund or whether we will build a new one from scratch. We have had a look at the premises and there are high requirements for manufacturing of a pharmaceutical preparation. One advantage is, of course, owning the premises ourselves, but that has not been decided yet, says Roar Adelsten.